Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing

Rose, Peter G.; Purpura, Denise; Petersen, Lisa

doi: 10.1097/CAD.0000000000000795

Four ovarian cancer patients with severe plantar palmar erythrodysesthesia or mucositis precluding further therapy from pegylated liposomal doxorubicin on the standard every 4 week schedule were able to be treated on every 2-week schedule without recurrence of plantar palmar erythrodysesthesia or stomatitis.

Division of Gynecologic Oncology, Women’s Health Institute, Cleveland Clinic Healthcare System, Cleveland, Ohio, USA

Correspondence to Peter G. Rose, MD, A81 9500 Euclid Ave, Cleveland, OH 44195, USA Tel: +1 216 444 1712; fax: +1 216 444 8551; e-mail:

Received December 17, 2018

Accepted March 29, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.